Genoray Co. Ltd (122310) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Genoray Co. Ltd KRW 4,201, price KRW 3,330, upside +26.2%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Genoray Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It provides C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services.
Show more
Genoray Co., Ltd. engages in the research, development, manufacture, and sale of medical and dental x-ray devices in South Korea. It provides C-ARM and mammography medical x-ray devices; and 2D, 3D, ENT, and IOS/IOX dental x-ray devices, as well as related maintenance and repair services. The company also exports its products to approximately 80 countries worldwide. Genoray Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea
Stock analysis
Genoray Co. Ltd (122310) currently trades at 3,330 KRW, while our model-based Fair Value estimate is 4,201 KRW, implying the stock looks roughly 20.7% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 6,750 KRW per share, and 14 of the 21 models we run sit above the 3,330 KRW price.
Bear case: the Earnings-Based group reads lowest at 655.82 KRW, and 7 of the 21 models stay below the price. Evidence for this calculation is medium.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Genoray Co. Ltd reported revenue of 108B KRW in FY2025 versus 74.3B KRW in FY2021, a compound +9.8%/yr. Reported net income was 758M KRW in FY2025, compounding −52.0%/yr from FY2021.
Key figures
Market cap 40.5B KRW (≈ $29.7M) · P/S ratio 0.38 · Dividend yield 7.5% · Net margin 0.7% · Return on equity 0.1% · Return on assets (EBIT) 6.6% · Operating margin −6.2% · Revenue (TTM) 108B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 26%, 122310 screens cheaper than that median.
Fair Value models
Bear 4,201 KRWFair Value 4,201 KRWBull 4,201 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.80/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−34.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−41.6%
Dividend (yield on the price)7.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−42% vs −16%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 0%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−2.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −4.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+26% · Top 25%
Profitability
Return on equity (TTM)0% · Below median
Return on assets−1% · Below median
Net margin (TTM)0% · Below median
Operating margin (TTM)−6% · Below median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)7.5% · Top 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genoray Co. Ltd (122310) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4,201 KRW versus a price of 3,330 KRW, about +26% upside (undervalued).
What is the fair value of 122310?
Our model-based fair value for Genoray Co. Ltd is 4,201 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,330 KRW.
What is the quality score of 122310?
Genoray Co. Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genoray Co. Ltd (122310)?
Our model-based price target is the fair value of 4,201 KRW (as of Sep 24, 2026) from 21 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Genoray Co. Ltd stock forecast for 2026?
Our models put fair value at 4,201 KRW, about +26% upside versus a price of 3,330 KRW (undervalued). The calculation is refreshed regularly with new filings.
What is the revenue of Genoray Co. Ltd (122310)?
Genoray Co. Ltd reported trailing-twelve-month revenue of about 108B KRW (latest available figure, as of Sep 24, 2026).
Does Genoray Co. Ltd pay a dividend?
Genoray Co. Ltd currently shows a dividend yield of about 7.51% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Genoray Co. Ltd (122310)?
For today's price to be fair in a discounted-cash-flow model, Genoray Co. Ltd would have to grow free cash flow by -2.2 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 122310 use?
Our models discount Genoray Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.28, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genoray Co. Ltd that is -2.2 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Genoray Co. Ltd (122310) delivered so far?
Over the past 5 years revenue at Genoray Co. Ltd grew +11.9 % a year. The price currently implies -2.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genoray Co. Ltd (122310) growing?
The median revenue growth in the sector is +1.8 % a year. That is the yardstick for the growth priced into Genoray Co. Ltd (-2.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genoray Co. Ltd (122310)?
The free-cash-flow yield on the price is 9.53 %: that much free cash flow Genoray Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genoray Co. Ltd (122310)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genoray Co. Ltd it is 4,201 KRW per share (as of Sep 24, 2026), against a price of 3,330 KRW. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Genoray Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 122310 trades below its calculated fair value: price 3,330 KRW, fair value 4,201 KRW, a gap of about +26% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 122310?
No. The price is what the market pays today (3,330 KRW); the fair value is what the company's own numbers justify (4,201 KRW). For Genoray Co. Ltd the two are 870.84 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genoray Co. Ltd worth?
The market values Genoray Co. Ltd at about 40.5B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,330 KRW; our models calculate a fair value of 4,201 KRW per share.
How solid is the balance sheet of Genoray Co. Ltd (122310)?
Balance-sheet figures for Genoray Co. Ltd (as of Sep 24, 2026): return on equity 0.1%. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 122310 from its 52-week high?
Genoray Co. Ltd trades at 3,330 KRW, about 32% below its 52-week high of 4,911 KRW and 6% above the low of 3,150 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 4,201 KRW is for.
Which stocks are comparable to Genoray Co. Ltd?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genoray Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,330 KRW, calculated fair value 4,201 KRW (+26%), Quality Score 61/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 122310 calculated?
We run Genoray Co. Ltd through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,201 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Genoray Co. Ltd currently trades 26 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genoray Co. Ltd (122310)?
The closing price on Sep 23, 2026 was 3,330 KRW. Our model-based fair value is 4,201 KRW, about +26% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genoray Co. Ltd right now?
The price is below even our cautious bear case (4,201 KRW). The market is more pessimistic than our downside scenario. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Genoray Co. Ltd
How large is the market capitalisation of Genoray Co. Ltd (122310)?
The market capitalisation of Genoray Co. Ltd is 40.5B KRW (≈ $29.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genoray Co. Ltd (122310)?
The price-to-sales ratio of Genoray Co. Ltd is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Genoray Co. Ltd (122310)?
The dividend yield of Genoray Co. Ltd is 7.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Genoray Co. Ltd (122310)?
The net margin of Genoray Co. Ltd is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genoray Co. Ltd (122310)?
The return on equity (ROE) of Genoray Co. Ltd is 0.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genoray Co. Ltd (122310)?
On an EBIT basis the return on assets of Genoray Co. Ltd is 6.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genoray Co. Ltd (122310)?
The operating margin of Genoray Co. Ltd is −6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genoray Co. Ltd (122310)?
Revenue at Genoray Co. Ltd is growing +0.9% versus a year earlier (3y avg +9.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genoray Co. Ltd (122310)?
Earnings per share at Genoray Co. Ltd are growing −93.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Genoray Co. Ltd (122310) carry?
The net debt of Genoray Co. Ltd is 9.2B KRW (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genoray Co. Ltd in the live analysis
One click puts Genoray Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
